|
KMID : 1142020210560020102
|
|
Blood Research
2021 Volume.56 No. 2 p.102 ~ p.108
|
|
|
Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
|
|
Hong Jun-Shik
Lee Yoo-Jin
Bae Sung-Hwa
Yi Jun-Ho
Park Sung-Woo
Chang Myung-Hee
Park Young-Hoon
Hyun Shin-Young
Chung Joo-Seop
Jang Ji-Eun
Jung Joo-Young
Jeon So-Yeon
Song Seo-Young
Kim Hawk
Kim Dae-Sik
Kim Sung-Hyun
Kim Min-Kyoung
Han Sang-Hoon
Park Seon-Yang
Kim Yoo-Jin
Lee Je-Hwan
|
|
|
Abstract
|
|
|
Background: To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea.
Methods: Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed.
Results: A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades ≥3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%).
Conclusion: Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes.
|
|
|
KEYWORD
|
|
|
5q deletion syndrome, Myelodysplastic syndrome, Lenalidomide, Anemia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|